Previously, screening for cardiovascular disease (CVD) focused on hyperlipidemia, obesity, and hypertension. However, approximately one half of AMIs occur in healthy men and women with normal or only slightly elevated plasma lipids. With new insights into cardiac disease and the ACS, novel biomarkers such as inflammatory markers, hormones, and other biomolecules indicating myocardial stress have been proposed. The question of what added benefit these novel markers have over existing markers can be a contentious debate. Some examples of other screening markers for CVD include:
- High-sensitivity C-reactive protein (hs-CRP)
- Homocysteine
- Myeloperoxidase (MPO)
